STXS
Price
$1.04
Change
+$0.08 (+8.33%)
Updated
Nov 5, 04:59 PM (EDT)
Capitalization
95.91M
5 days until earnings call
Intraday BUY SELL Signals
VCYT
Price
$24.00
Change
-$28.52 (-54.30%)
Updated
Nov 5 closing price
Capitalization
1.93B
116 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

STXS vs VCYT

STXS vs VCYT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
STXS vs. VCYT commentary
Nov 06, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is STXS is a StrongBuy and VCYT is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for STXS with price predictions
Nov 04, 2026

STXS in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 29, 2026

STXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 29 cases where STXS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where STXS's RSI Oscillator exited the oversold zone, 21 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 67 cases where STXS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

Following a +2.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where STXS advanced for three days, in 156 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for STXS turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 44 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where STXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for STXS entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. STXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.834) is normal, around the industry mean (5.069). P/E Ratio (-3.988) is within average values for comparable stocks, (40.009). Projected Growth (PEG Ratio) (12.600) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.248) is also within normal values, averaging (56.876).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for VCYT with price predictions
Nov 04, 2026

VCYT's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for VCYT turned positive on October 21, 2026. Looking at past instances where VCYT's MACD turned positive, the stock continued to rise in 44 of 51 cases over the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on VCYT as a result. In 75 of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.

VCYT moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for VCYT crossed bullishly above the 50-day moving average on October 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.

Following a +7.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCYT advanced for three days, in 205 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

Bearish Trend Analysis

The 10-day RSI Indicator for VCYT moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 23 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCYT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

VCYT broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. VCYT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.390) is normal, around the industry mean (66.911). P/E Ratio (16.667) is within average values for comparable stocks, (2.514). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (9.775).

The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCYT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

FUNDAMENTALS RATINGS
STXS vs VCYT: Fundamental Ratings
STXS
VCYT
OUTLOOK RATING
1..100
7037
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
72
Overvalued
PROFIT vs RISK RATING
1..100
10084
SMR RATING
1..100
10075
PRICE GROWTH RATING
1..100
8939
P/E GROWTH RATING
1..100
1294
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VCYT's Valuation (72) in the Biotechnology industry is in the same range as STXS (94) in the Medical Specialties industry. This means that VCYT’s stock grew similarly to STXS’s over the last 12 months.

VCYT's Profit vs Risk Rating (84) in the Biotechnology industry is in the same range as STXS (100) in the Medical Specialties industry. This means that VCYT’s stock grew similarly to STXS’s over the last 12 months.

VCYT's SMR Rating (75) in the Biotechnology industry is in the same range as STXS (100) in the Medical Specialties industry. This means that VCYT’s stock grew similarly to STXS’s over the last 12 months.

VCYT's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for STXS (89) in the Medical Specialties industry. This means that VCYT’s stock grew somewhat faster than STXS’s over the last 12 months.

STXS's P/E Growth Rating (12) in the Medical Specialties industry is significantly better than the same rating for VCYT (94) in the Biotechnology industry. This means that STXS’s stock grew significantly faster than VCYT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
STXSVCYT
RSI
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
72%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 14 days ago
75%
Bullish Trend 2 days ago
74%
Declines
ODDS (%)
Bearish Trend 7 days ago
81%
Bearish Trend 4 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
N/A
COMPARISON
Comparison
Nov 06, 2026
Stock price -- (STXS: $0.96 vs. VCYT: $52.52)
Brand notoriety: STXS and VCYT are both not notable
STXS represents the Pharmaceuticals: Other, while VCYT is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: STXS: 210% vs. VCYT: 132%
Market capitalization -- STXS: $95.91M vs. VCYT: $1.93B
STXS [@Pharmaceuticals: Other] is valued at $95.91M. VCYT’s [@Medical Specialties] market capitalization is $1.93B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $165.52B. The market cap for tickers in the [@Medical Specialties] industry ranges from $27 to $4.39T. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.91B. The average market capitalization across the [@Medical Specialties] industry is $21.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

STXS’s FA Score shows that 1 FA rating(s) are green while VCYT’s FA Score has 0 green FA rating(s).

  • STXS’s FA Score: 1 green, 4 red.
  • VCYT’s FA Score: 0 green, 5 red.
According to our system of comparison, both STXS and VCYT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

STXS’s TA Score shows that 4 TA indicator(s) are bullish while VCYT’s TA Score has 5 bullish TA indicator(s).

  • STXS’s TA Score: 4 bullish, 3 bearish.
  • VCYT’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both STXS and VCYT are a good buy in the short-term.

Price Growth

STXS (@Pharmaceuticals: Other) experienced а -1.35% price change this week, while VCYT (@Medical Specialties) price change was +4.39% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.36%. For the same industry, the average monthly price growth was +0.95%, and the average quarterly price growth was +12.45%.

The average weekly price growth across all stocks in the @Medical Specialties industry was -9.05%. For the same industry, the average monthly price growth was -8.17%, and the average quarterly price growth was +36.11%.

Reported Earning Dates

STXS is expected to report earnings on Nov 10, 2026.

VCYT is expected to report earnings on Mar 01, 2027.

Industries' Descriptions

@Pharmaceuticals: Other (+0.36% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Medical Specialties (-9.05% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

View a ticker or compare two or three
Interact to see
Advertisement

STXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, STXS has been loosely correlated with SMTI. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if STXS jumps, then SMTI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STXS
1D Price
Change %
STXS100%
+13.55%
SMTI - STXS
38%
Loosely correlated
+0.50%
TWST - STXS
36%
Loosely correlated
+1.63%
CERS - STXS
35%
Loosely correlated
+3.21%
VCYT - STXS
33%
Poorly correlated
+4.43%
SHC - STXS
32%
Poorly correlated
+2.25%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EDGU31.910.50
+1.59%
3EDGE Dynamic US Equity ETF (EDGU)
SOLM7.770.12
+1.57%
Amplify Solana 3% Monthly Option Income ETF (SOLM)
QBSV27.310.26
+0.98%
AllianzIM U.S Equity Buffer5 ETF (QBSV)
JEMA56.870.43
+0.77%
JPMorgan ActiveBuilders Emerging Markets Equity ETF (JEMA)
XFLT16.700.11
+0.66%
XAI Floating Rate & Alternative Income Trust